Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45. 2001. View Article : Google Scholar

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, et al: Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 71:603–613. 2011. View Article : Google Scholar :

Debes JD and Tindall DJ: The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 187:1–7. 2002. View Article : Google Scholar : PubMed/NCBI

Duffy MJ: Estrogen receptors: Role in breast cancer. Crit Rev Clin Lab Sci. 43:325–347. 2006. View Article : Google Scholar : PubMed/NCBI

Balk SP and Knudsen KE: AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 6:e0012008. View Article : Google Scholar : PubMed/NCBI

Lamb AD, Massie CE and Neal DE: The transcriptional programme of the androgen receptor (AR) in prostate cancer. BJU Int. 113:358–366. 2014. View Article : Google Scholar

Russo J and Russo IH: The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol. 102:89–96. 2006. View Article : Google Scholar : PubMed/NCBI

Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, Conaway M, Wang H, Korach KS, Bocchinfuso W, et al: Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms. Int J Cancer. 127:1748–1757. 2010. View Article : Google Scholar : PubMed/NCBI

Samavat H and Kurzer MS: Estrogen metabolism and breast cancer. Cancer Lett. 356:231–243. 2015. View Article : Google Scholar :

DeMichele A and Chodosh LA: 'Braking' the cycle of resistance in endocrine therapy for breast cancer. Clin Cancer Res. 21:4999–5001. 2015. View Article : Google Scholar : PubMed/NCBI

Horwich A, Parker C, de Reijke T and Kataja V; ESMO Guidelines Working Group: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24(Suppl 6): vi106–vi114. 2013. View Article : Google Scholar : PubMed/NCBI

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al European Association of Urology: EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 65:124–137. 2014. View Article : Google Scholar

Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, et al: Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 14:19–30. 2016. View Article : Google Scholar : PubMed/NCBI

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, et al European Association of Urology: EAU guidelines on prostate cancer: Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 65:467–479. 2014. View Article : Google Scholar

Wise HM, Hermida MA and Leslie NR: Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond). 131:197–210. 2017. View Article : Google Scholar

Bilusic M, Madan RA and Gulley JL: Immunotherapy of prostate cancer: Facts and hopes. Clin Cancer Res. 23:6764–6770. 2017. View Article : Google Scholar : PubMed/NCBI

Kim YJ, Jung SY and Kim K: Survival benefit of radiotherapy after surgery in de novo stage IV breast cancer: A population-based propensity-score matched analysis. Sci Rep. 9:85272019. View Article : Google Scholar : PubMed/NCBI

Yao Y, Chu Y, Xu B, Hu Q and Song Q: Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Med. 8:554–563. 2019. View Article : Google Scholar : PubMed/NCBI

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, et al: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 34:3069–3103. 2016. View Article : Google Scholar : PubMed/NCBI

Alvarez Lopez I, de la Haba Rodriguez J, Ruiz Simon A, Bellet Ezquerra M, Calvo Martinez L, Garcia Estevez L, Rodriguez Lescure A and Isla Casado D: SEOM (Spanish Society for Medical Oncology): SEOM clinical guidelines for the treatment of metastatic breast cancer. Clin Transl Oncol. 12:719–723. 2010. View Article : Google Scholar

Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S and Cardoso F; Committee EG: ESMO Guidelines Committee: Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 26(Suppl 5): v8–v30. 2015. View Article : Google Scholar

Goetz Mp, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison Kh, Blair SL, Burstein HJ, Dang C, Elias ad, et al: NCCN guidelines insights: Breast cancer, version 3.2018. J Natl Compr Canc Netw. 17:118–126. 2019. View Article : Google Scholar : PubMed/NCBI

Ahmed S, Sami A and Xiang J: HER2-directed therapy: Current treatment options for HER2-positive breast cancer. Breast Cancer. 22:101–116. 2015. View Article : Google Scholar : PubMed/NCBI

Esteva FJ, Hubbard-Lucey VM, Tang J and Pusztai L: Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20:e175–e186. 2019. View Article : Google Scholar : PubMed/NCBI

Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP and Puduvalli VK: Brain metastasis from prostate carcinoma: The M.D. Anderson Cancer Center experience. Cancer. 98:363–368. 2003. View Article : Google Scholar : PubMed/NCBI

Lee GT, Kang DI, Ha YS, Jung YS, Chung J, Min K, Kim TH, Moon KH, Chung JM, Lee DH, et al: Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction. Br J Cancer. 110:1634–1644. 2014. View Article : Google Scholar : PubMed/NCBI

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, et al: Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases. Clin Cancer Res. 25:2737–2744. 2019. View Article : Google Scholar : PubMed/NCBI

Yao B, Wang J, Qu S, Liu Y, Jin Y, Lu J, Bao Q, Li L, Yuan H and Ma C: Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer. Cell Death Dis. 10:282019. View Article : Google Scholar : PubMed/NCBI

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al: The nuclear receptor superfamily: The second decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI

Girdler F and Brotherick I: The oestrogen receptors (ER alpha and ER beta) and their role in breast cancer: A review. Breast. 9:194–200. 2000. View Article : Google Scholar

Suzuki H, Ueda T, Ichikawa T and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 10:209–216. 2003. View Article : Google Scholar : PubMed/NCBI

Carroll JS: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer. Eur J Endocrinol. 175:R41–R49. 2016. View Article : Google Scholar : PubMed/NCBI

Russell DW and Wilson JD: Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem. 63:25–61. 1994. View Article : Google Scholar : PubMed/NCBI

Marcelli M and Cunningham GR: Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 84:3463–3468. 1999.PubMed/NCBI

Sommer S and Fuqua SA: Estrogen receptor and breast cancer. Semin Cancer Biol. 11:339–352. 2001. View Article : Google Scholar : PubMed/NCBI

Alluri PG, Speers C and Chinnaiyan AM: Estrogen receptor mutations and their role in breast cancer progression. Breast Cancer Res. 16:4942014. View Article : Google Scholar : PubMed/NCBI

Mc Cormack O, Chung WY, Fitzpatrick P, Cooke F, Flynn B, Harrison M, Fox E, Gallagher E, McGoldrick A, Dervan PA, et al: Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: Progesterone receptor B hypermethylation in breast cancer. Breast Cancer Res Treat. 111:45–53. 2008. View Article : Google Scholar

Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD and Mao Q: Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol. 73:845–854. 2008. View Article : Google Scholar

Wu X, Zhang X, Zhang H, Su P, Li W, Li L, Wang Y, Liu W, Gao P and Zhou G: Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sci. 103:959–967. 2012. View Article : Google Scholar : PubMed/NCBI

Grimm SL, Hartig SM and Edwards DP: Progesterone receptor signaling mechanisms. J Mol Biol. 428:3831–3849. 2016. View Article : Google Scholar : PubMed/NCBI

Dowsett M: Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer. 8:191–195. 2001. View Article : Google Scholar : PubMed/NCBI

Kurokawa H and Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res. 9:511S–515S. 2003.PubMed/NCBI

Hsu JL and Hung MC: The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 35:575–588. 2016. View Article : Google Scholar : PubMed/NCBI

Järvinen TAH, Pelto-Huikko M, Holli K and Isola J: Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol. 156:29–35. 2000. View Article : Google Scholar : PubMed/NCBI

Fan W, Chang J and Fu P: Endocrine therapy resistance in breast cancer: Current status, possible mechanisms and overcoming strategies. Future Med Chem. 7:1511–1519. 2015. View Article : Google Scholar : PubMed/NCBI

Ding J, Wang X, Zhang Y, Sang X, Yi J, Liu C, Liu Z, Wang M, Zhang N, Xue Y, et al: Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Ka inhibition through the transcriptional regulation of ERa. Cancer Lett. 440-441:54–63. 2019. View Article : Google Scholar

Blessing AM, Rajapakshe K, Reddy Bollu L, Shi Y, White MA, Pham AH, Lin C, Jonsson P, Cortes CJ, Cheung E, et al: Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy. 13:506–521. 2017. View Article : Google Scholar :

McCartan D, Bolger jC, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill AD, Gaora pO, et al: Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res. 72:220–229. 2012. View Article : Google Scholar

Sahin I, Mega AE and Carneiro BA: Androgen receptor-independent prostate cancer: An emerging clinical entity. Cancer Biol Ther. 19:347–348. 2018. View Article : Google Scholar : PubMed/NCBI

Chen CD and Sawyers CL: NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol. 22:2862–2870. 2002. View Article : Google Scholar : PubMed/NCBI

Zhou Y, Eppenberger-Castori S, Eppenberger U and Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer. 12(Suppl 1): S37–S46. 2005. View Article : Google Scholar : PubMed/NCBI

Oida K, Matsuda A, Jung K, Xia Y, Jang H, Amagai Y, Ahn G, Nishikawa S, Ishizaka S, Jensen-Jarolim E, et al: Nuclear factor-KB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells. Sci Rep. 4:40572014. View Article : Google Scholar

Malinen M, Niskanen EA, Kaikkonen MU and Palvimo JJ: Crosstalk between androgen and pro-inflammatory signaling remodels androgen receptor and NF-κB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res. 45:619–630. 2017. View Article : Google Scholar

Péant B, Diallo JS, Lessard L, Delvoye N, Le Page C, Saad F and Mes-Masson AM: Regulation of IkappaB kinase epsilon expression by the androgen receptor and the nuclear factor-kappaB transcription factor in prostate cancer. Mol Cancer Res. 5:87–94. 2007. View Article : Google Scholar : PubMed/NCBI

Yuan X, Cai C, Chen S, Chen S, Yu Z and Balk SP: Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 33:2815–2825. 2014. View Article : Google Scholar

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, et al: NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol. 175:489–499. 2009. View Article : Google Scholar : PubMed/NCBI

Jin R, Yamashita H, Yu X, Wang J, Franco OE, Wang Y, Hayward SW and Matusik RJ: Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene. 34:3700–3710. 2015. View Article : Google Scholar

Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP and Gao AC: NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants. Mol Cancer Ther. 12:1629–1637. 2013. View Article : Google Scholar : PubMed/NCBI

Staal J and Beyaert R: Inflammation and NF-kappaB signaling in prostate cancer: Mechanisms and clinical implications. Cells. 7:72018. View Article : Google Scholar

Sas L, Lardon F, Vermeulen PB, Hauspy J, Van Dam P, Pauwels P, Dirix LY and Van Laere SJ: The interaction between ER and NFkB in resistance to endocrine therapy. Breast Cancer Res. 14:2122012. View Article : Google Scholar

Shao N, Lu Z, Zhang Y, Wang M, Li W, Hu Z, Wang S and Lin Y: Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway. Cancer Lett. 364:165–172. 2015. View Article : Google Scholar : PubMed/NCBI

Nakshatri H Jr, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr and Sledge GW Jr: Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol. 17:3629–3639. 1997. View Article : Google Scholar : PubMed/NCBI

Belguise K and Sonenshein GE: PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J Clin Invest. 117:4009–4021. 2007.PubMed/NCBI

Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D and Sonenshein GE: Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol. 9:470–478. 2007. View Article : Google Scholar : PubMed/NCBI

Wang X, Belguise K, O'Neill CF, Sanchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, et al: RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol. 29:3832–3844. 2009. View Article : Google Scholar : PubMed/NCBI

Pradhan M, Baumgarten SC, Bembinster LA and Frasor J: CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter. Mol Cell Biol. 32:569–575. 2012. View Article : Google Scholar :

Frasor J, El-Shennawy L, Stender JD and Kastrati I: NFkB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol. 418:235–239. 2015. View Article : Google Scholar

Zeligs KP, Neuman MK and Annunziata CM: Molecular pathways: The balance between cancer and the immune system challenges the therapeutic specificity of targeting nuclear factor-kB signaling for cancer treatment. Clin Cancer Res. 22:4302–4308. 2016. View Article : Google Scholar : PubMed/NCBI

Sun SC: Non-canonical NF-κB signaling pathway. Cell Res. 21:71–85. 2011. View Article : Google Scholar

Kastrati I, Siklos MI, Calderon-Gierszal EL, El-Shennawy L, Georgieva G, Thayer EN, Thatcher GR and Frasor J: Dimethyl fumarate inhibits the nuclear factor kB pathway in breast cancer cells by covalent modification of p65 protein. J Biol Chem. 291:3639–3647. 2016. View Article : Google Scholar

Vrábel D, Pour L and Ševčíková S: The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 34:56–66. 2019. View Article : Google Scholar

Park MH and Hong JT: Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells. 5:52016. View Article : Google Scholar

Maubach G, Feige MH, Lim MCC and Naumann M: NF-kappaB-inducing kinase in cancer. Biochim Biophys Acta Rev Cancer. 1871:40–49. 2019. View Article : Google Scholar

Gray CM, Remouchamps C, McCorkell KA, Solt LA, Dejardin E, Orange JS and May MJ: Noncanonical NF-κB signaling is limited by classical NF-κB activity. Sci Signal. 7:ra132014. View Article : Google Scholar

Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, et al: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 16:286–294. 2010. View Article : Google Scholar : PubMed/NCBI

Ammirante M, Luo JL, Grivennikov S, Nedospasov S and Karin M: B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 464:302–305. 2010. View Article : Google Scholar : PubMed/NCBI

Mendonca MS, Turchan WT, Alpuche ME, Watson CN, Estabrook NC, Chin-Sinex H, Shapiro JB, Imasuen-Williams IE, Rangel G, Gilley DP, et al: DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 112:318–326. 2017. View Article : Google Scholar : PubMed/NCBI

Kendellen MF, Bradford JW, Lawrence CL, Clark KS and Baldwin AS: Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells. Oncogene. 33:1297–1305. 2014. View Article : Google Scholar

Streicher KL, Willmarth NE, Garcia J, Boerner JL, Dewey TG and Ethier SP: Activation of a nuclear factor kappaB/interleukin-1 positive feedback loop by amphiregulin in human breast cancer cells. Mol Cancer Res. 5:847–861. 2007. View Article : Google Scholar : PubMed/NCBI

Saha S, Mukherjee S, Khan P, Kajal K, Mazumdar M, Manna A, Mukherjee S, De S, Jana D, Sarkar DK, et al: Aspirin suppresses the acquisition of chemoresistance in breast cancer by disrupting an NFkappaB-IL6 signaling axis responsible for the generation of cancer stem cells. Cancer Res. 76:2000–2012. 2016. View Article : Google Scholar : PubMed/NCBI

Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI

Stender JD, Nwachukwu JC, Kastrati I, Kim Y, Strid T, Yakir M, Srinivasan S, Nowak J, Izard T and Rangarajan ES: et al Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells. Mol Cell. 65:1122–1135.e1125. 2017. View Article : Google Scholar : PubMed/NCBI

Osborne CK and Schiff R: Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 62:233–247. 2011. View Article : Google Scholar

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R and Isaacs WB: Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 67:470–479. 2015. View Article : Google Scholar

Crona DJ and Whang YE: Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance. Cancers (Basel). 9:92017. View Article : Google Scholar

Lee JW, Kim GY and Kim JH: Androgen receptor is up-regulated by a BLT2-linked pathway to contribute to prostate cancer progression. Biochem Biophys Res Commun. 420:428–433. 2012. View Article : Google Scholar : PubMed/NCBI

Penney RB and Roy D: Thioredoxin-mediated redox regulation of resistance to endocrine therapy in breast cancer. Biochim Biophys Acta. 1836:60–79. 2013.PubMed/NCBI

Bakin RE, Gioeli D, Bissonette EA and Weber MJ: Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Res. 63:1975–1980. 2003.PubMed/NCBI

Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M and Wu H: Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72:1878–1889. 2012. View Article : Google Scholar : PubMed/NCBI

Heckler MM, Thakor H, Schafer CC and Riggins RB: ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER⁺ breast cancer. FEBS J. 281:2431–2442. 2014. View Article : Google Scholar : PubMed/NCBI

Hong SK, Jeong JH, Chan AM and Park JI: AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion. Exp Cell Res. 319:1732–1743. 2013. View Article : Google Scholar : PubMed/NCBI

Wang H, Zhang L, Fu Y, Fang F, Jiang Y, Dong Y and Zhu W: CSL regulates AKT to mediate androgen independence in prostate cancer progression. Prostate. 76:140–150. 2016. View Article : Google Scholar

Lu S, Ren C, Liu Y and Epner DE: PI3K-Akt signaling is involved in the regulation of p21(WAF/CIP) expression and androgen-independent growth in prostate cancer cells. Int J Oncol. 28:245–251. 2006.

Lee SO, Lou W, Nadiminty N, Lin X and Gao AC: Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate. 64:160–167. 2005. View Article : Google Scholar : PubMed/NCBI

Rodriguez M, Luo W, Weng J, Zeng L, Yi Z, Siwko S and Liu M: PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-κB. Oncogenesis. 3:e1142014. View Article : Google Scholar

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, et al: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI

Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK and Chi SG: Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling pathways. Oncogene. 22:4314–4332. 2003. View Article : Google Scholar : PubMed/NCBI

Holloway JN, Murthy S and El-Ashry D: A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: The role of nuclear factor-kappaB. Mol Endocrinol. 18:1396–1410. 2004. View Article : Google Scholar : PubMed/NCBI

Tian M and Schiemann WP: TGF-beta stimulation of EMT programs elicits non-genomic ER-alpha activity and anti-estrogen resistance in breast cancer cells. J Cancer Metastasis Treat. 3:150–160. 2017. View Article : Google Scholar :

Penninkhof F, Grootegoed JA and Blok LJ: Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells. Oncogene. 23:5607–5615. 2004. View Article : Google Scholar : PubMed/NCBI

Brown NE, Paluch AM, Nashu MA, Komurov K and Waltz SE: Tumor cell autonomous RON receptor expression promotes prostate cancer growth under conditions of androgen deprivation. Neoplasia. 20:917–929. 2018. View Article : Google Scholar : PubMed/NCBI

House CD, Jordan E, Hernandez L, Ozaki M, James JM, Kim M, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, et al: NFkappaB promotes ovarian tumorigenesis via classical pathways that support proliferative cancer cells and alternative pathways that support ALDH(+) cancer stem-like cells. Cancer Res. 77:6927–6940. 2017. View Article : Google Scholar : PubMed/NCBI

Han B, Zhou B, Qu Y, Gao B, Xu Y, Chung S, Tanaka H, Yang W, Giuliano AE and Cui X: FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. Oncogene. 37:1399–1408. 2018. View Article : Google Scholar :

Litchfield LM, Appana SN, Datta S and Klinge CM: COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells. Mol Cell Endocrinol. 382:358–367. 2014. View Article : Google Scholar

Rwigemera A, Mamelona J and Martin LJ: Inhibitory effects of fucoxanthinol on the viability of human breast cancer cell lines MCF-7 and MDA-MB-231 are correlated with modulation of the NF-kappaB pathway. Cell Biol Toxicol. 30:157–167. 2014. View Article : Google Scholar : PubMed/NCBI

Vogel CF, Li W, Wu D, Miller JK, Sweeney C, Lazennec G, Fujisawa Y and Matsumura F: Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression. Arch Biochem Biophys. 512:78–86. 2011. View Article : Google Scholar : PubMed/NCBI

Bekki K, Vogel H, Li W, Ito T, Sweeney C, Haarmann- Stemmann T, Matsumura F and Vogel CF: The aryl hydrocarbon receptor (AhR) mediates resistance to apoptosis induced in breast cancer cells. Pestic Biochem Physiol. 120:5–13. 2015. View Article : Google Scholar : PubMed/NCBI

Shah KN, Wilson EA, Malla R, Elford HL and Faridi JS: Targeting ribonucleotide reductase M2 and NF-kappaB activation with didox to circumvent tamoxifen resistance in breast cancer. Mol Cancer Ther. 14:2411–2421. 2015. View Article : Google Scholar : PubMed/NCBI

Yde CW, Emdal KB, Guerra B and Lykkesfeldt AE: NFkB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res Treat. 135:67–78. 2012. View Article : Google Scholar : PubMed/NCBI

Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 20:7342–7351. 2001. View Article : Google Scholar : PubMed/NCBI

Srinivasan S, Kumar R, Koduru S, Chandramouli A and Damodaran C: Inhibiting TNF-mediated signaling: A novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis. 15:153–161. 2010. View Article : Google Scholar :

Liu VWS, Yau WL, Tam CW, Yao KM and Shiu SY: Melatonin inhibits androgen receptor splice variant-7 (AR-V7)-induced nuclear factor-kappa B (NF-kappaB) activation and NF-kappaB activator-induced AR-V7 expression in prostate cancer cells: Potential implications for the use of melatonin in castration-resistant prostate cancer (CRPC) therapy. Int J Mol Sci. 18:182017. View Article : Google Scholar

Zerbini LF, Wang Y, Cho JY and Libermann TA: Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res. 63:2206–2215. 2003.PubMed/NCBI

Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB and Lokeshwar BL: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 67:6854–6862. 2007. View Article : Google Scholar : PubMed/NCBI

Lee SO, Pinder E, Chun JY, Lou W, Sun M and Gao AC: Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate. 68:85–91. 2008. View Article : Google Scholar

Jeong JH, Park SJ, Dickinson SI and Luo JL: A constitutive intrinsic inflammatory signaling circuit composed of miR-196b, Meis2, PPP3CC, and p65 drives prostate cancer castration resistance. Mol Cell. 65:154–167. 2017. View Article : Google Scholar : PubMed/NCBI

McCall P, Bennett L, Ahmad I, Mackenzie LM, Forbes IW, Leung HY, Sansom OJ, Orange C, Seywright M, Underwood MA, et al: NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer. 107:1554–1563. 2012. View Article : Google Scholar : PubMed/NCBI

Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T and Eto M: Protein kinase C regulates Twist1 expression via NF-κB in prostate cancer. Endocr Relat Cancer. 24:171–180. 2017. View Article : Google Scholar : PubMed/NCBI

Pratt MAC, Bishop TE, White D, Yasvinski G, Menard M, Niu MY and Clarke R: Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: Roles in growth and hormone independence. Mol Cell Biol. 23:6887–6900. 2003. View Article : Google Scholar : PubMed/NCBI

Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-Castori S and Benz CC: Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer. 7:592007. View Article : Google Scholar : PubMed/NCBI

Semlali A, Oliva J, Badia E, Pons M and Duchesne MJ: Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cells. J Steroid Biochem Mol Biol. 88:247–259. 2004. View Article : Google Scholar : PubMed/NCBI

Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB and Clarke R: NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Mol Cell Biol. 35:379–390. 2015. View Article : Google Scholar

Yamaguchi N, Nakayama Y and Yamaguchi N: Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6. J Biol Chem. 292:8136–8148. 2017. View Article : Google Scholar : PubMed/NCBI

Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, et al: Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 73:3470–3480. 2013. View Article : Google Scholar : PubMed/NCBI

Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC and Clarke R: BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 24:2040–2055. 2010. View Article : Google Scholar : PubMed/NCBI

Riggins RB, Zwart A, Nehra R and Clarke R: The nuclear factor kB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther. 4:33–41. 2005. View Article : Google Scholar : PubMed/NCBI

Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q and Gao AC: Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 70:3309–3319. 2010. View Article : Google Scholar : PubMed/NCBI

Nadiminty N, Chun JY, Lou W, Lin X and Gao AC: NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation. Prostate. 68:1725–1733. 2008. View Article : Google Scholar : PubMed/NCBI

Nadiminty N, Dutt S, Tepper C and Gao AC: Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells. Prostate. 70:276–287. 2010.

Mehraein-Ghomi F, Church DR, Schreiber CL, Weichmann MA, Basu HS and Wilding G: Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated ARser81. Genes Cancer. 6:428–444. 2015.PubMed/NCBI

Nadiminty N, Tummala R, Liu C, Lou W, Evans CP and Gao AC: NF-kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther. 14:1884–1895. 2015. View Article : Google Scholar : PubMed/NCBI

Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT and Gao AC: Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr Relat Cancer. 21:435–442. 2014. View Article : Google Scholar : PubMed/NCBI

House CD, Grajales V, Ozaki M, Jordan E, Wubneh H, Kimble DC, James JM, Kim MK and Annunziata CM: Ikke cooperates with either MEK or non-canonical NF-κB driving growth of triple-negative breast cancer cells in different contexts. BMC Cancer. 18:5952018. View Article : Google Scholar

Kim YR, Kim IJ, Kang TW, Choi C, Kim KK, Kim MS, Nam KI and Jung C: HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis. Oncogene. 33:4558–4567. 2014. View Article : Google Scholar

Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G and Bonavida B: Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Oncogene. 23:4993–5003. 2004. View Article : Google Scholar : PubMed/NCBI

Domingo-Domenech J, Oliva C, Rovira A, Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C, Dang L, et al: Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 12:5578–5586. 2006. View Article : Google Scholar : PubMed/NCBI

Tsai CH, Tzeng SF, Hsieh SC, Yang YC, Hsiao YW, Tsai MH and Hsiao PW: A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer. Sci Rep. 7:156242017. View Article : Google Scholar : PubMed/NCBI

Nathan S, Ma Y, Tomita YA, De Oliveira E, Brown ML and Rosen EM: BRCA1-mimetic compound NSC35446. HCl inhibits IKKB expression by reducing estrogen receptor-a occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells. Breast Cancer Res Treat. 166:681–693. 2017. View Article : Google Scholar : PubMed/NCBI

Jiang L, Wang P, Sun YJ and Wu YJ: Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 38:2652019. View Article : Google Scholar

Coker-Gurkan A, Celik M, Ugur M, Arisan ED, Obakan-Yerlikaya P, Durdu ZB and Palavan-Unsal N: Curcumin inhibits autocrine growth hormone-mediated invasion and metastasis by targeting NF-κB signaling and polyamine metabolism in breast cancer cells. Amino Acids. 50:1045–1069. 2018. View Article : Google Scholar : PubMed/NCBI

Li J, Xiang S, Zhang Q, Wu J, Tang Q, Zhou J, Yang L, Chen Z and Hann SS: Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. J Exp Clin Cancer Res. 34:462015. View Article : Google Scholar

Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I and St Clair WH: Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther. 6:2048–2056. 2007. View Article : Google Scholar : PubMed/NCBI

Lundqvist J, Yde CW and Lykkesfeldt AE: 1a,25-dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells. Steroids. 85:30–35. 2014. View Article : Google Scholar : PubMed/NCBI

deGraffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW and Weiss GR: NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol. 15:885–890. 2004. View Article : Google Scholar : PubMed/NCBI

Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA and Krasil'nikov MA: NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis. Mol Cell Biochem. 324:65–71. 2009. View Article : Google Scholar

Xu Y, Fang F, Miriyala S, Crooks PA, Oberley TD, Chaiswing L, Noel T, Holley AK, Zhao Y, Kiningham KK, et al: KEAP1 is a redox sensitive target that arbitrates the opposing radiosensitive effects of parthenolide in normal and cancer cells. Cancer Res. 73:4406–4417. 2013. View Article : Google Scholar : PubMed/NCBI

Josson S, Xu Y, Fang F, Dhar SK, St Clair DK and St Clair WH: RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene. 25:1554–1559. 2006. View Article : Google Scholar

Tan C, Hu W, He Y, Zhang Y, Zhang G, Xu Y and Tang J: Cytokine-mediated therapeutic resistance in breast cancer. Cytokine. 108:151–159. 2018. View Article : Google Scholar : PubMed/NCBI

Khurana N and SIKKa SC: Targeting crosstalk between Nrf-2, NF-κB and androgen receptor signaling in prostate cancer. Cancers (Basel). 10:102018. View Article : Google Scholar

Ahmed KM, Zhang H and Park CC: NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 73:3737–3748. 2013. View Article : Google Scholar : PubMed/NCBI

Chaturvedi MM, Sung B, Yadav VR, Kannappan R and Aggarwal BB: NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 30:1615–1630. 2011. View Article : Google Scholar

Lessard L, Begin LR, Gleave ME, Mes-Masson AM and Saad F: Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI

Zhang Y, Xu Z, Ding J, Tan C, Hu W, Li Y, Huang W and Xu Y: HZ08 suppresses RelB-activated MnSOD expression and enhances Radiosensitivity of prostate Cancer cells. J Exp Clin Cancer Res. 37:1742018. View Article : Google Scholar : PubMed/NCBI